A 58-year-old man from Delhi presents with progressive jaundice for 3 weeks, pale stools, and dark urine. On examination, he has a palpable gallbladder and no hepatomegaly. Serum bilirubin is 8.2 mg/dL (direct 6.8 mg/dL), ALP 280 IU/L, ALT 95 IU/L. Ultrasound abdomen shows dilated intrahepatic bile ducts, dilated common bile duct (12 mm), and a normal gallbladder with no stones. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient presents with **obstructive jaundice** with clinical and biochemical evidence of **extrahepatic cholestasis** (dilated CBD on ultrasound, elevated ALP and direct bilirubin). The ultrasound has identified the obstruction but NOT its **cause** or **exact level**. ## Why MRCP/CT Is the Next Step **Key Point:** In obstructive jaundice with dilated ducts but no visible stone on ultrasound, **cross-sectional imaging (CT with MRCP or dedicated MRCP)** is mandatory before intervention to: - Identify the **cause** of obstruction (pancreatic head cancer, cholangiocarcinoma, ampullary lesion, stricture, intrahepatic stones) - Determine the **level** of obstruction (distal CBD, intrahepatic, hilar) - Guide choice of intervention (ERCP vs. PTC vs. surgical exploration) **High-Yield:** Ultrasound is a screening tool; it identifies **dilation** but cannot reliably characterize the **obstructing lesion**. MRCP has 90%+ sensitivity for detecting stones and masses and is the gold standard for defining ductal anatomy. **Clinical Pearl:** Courvoisier's sign (palpable gallbladder + jaundice) suggests **malignancy** rather than stone — this patient needs imaging to rule out pancreatic or biliary cancer before any endoscopic or surgical intervention. ## Why Other Options Are Premature | Option | Why Not Correct | |--------|------------------| | Direct ERCP | Blind ERCP without knowing the cause risks perforation, misses malignancy, and may not address the true obstruction. ERCP is **therapeutic**, not diagnostic, in this setting. | | Ursodeoxycholic acid | Inappropriate for obstructive (extrahepatic) jaundice; this drug is for intrahepatic cholestasis. Obstruction must be relieved, not medically managed. | | Supportive care alone | Obstructive jaundice carries risk of ascending cholangitis, hepatic dysfunction, and coagulopathy. Prolonged obstruction from malignancy worsens prognosis. | ## Diagnostic Algorithm ```mermaid flowchart TD A[Jaundice + dilated CBD on US]:::outcome --> B{Cause identified on US?}:::decision B -->|Stone visible| C[ERCP + sphincterotomy]:::action B -->|No stone, cause unclear| D[CT/MRCP to characterize lesion]:::action D --> E{Malignancy?}:::decision E -->|Yes| F[Staging + surgical/oncology consult]:::action E -->|No benign stricture/stone| G[ERCP or PTC as appropriate]:::action F --> H[Palliative or curative intervention]:::outcome G --> I[Drainage achieved]:::outcome ``` [cite:Sabiston Textbook of Surgery Ch 56]